Helius Medical Technologies

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Helius Medical Technologies reports Q1 revenue, eyes CMS reimbursement boost

Helius Medical Technologies navigated Q1 2024 with a focus on reimbursement, FDA approval, and financial sustainability, supported by financing and market expansion initiatives.
Progress in securing reimbursement, expanding market reach, and addressing demand signals growth potential and market acceptance for the company's products.
Challenges in achieving profitability and executing development plans underscore the importance of timely reimbursement and effective operational strategies.

Helius Medical Technologies navigates revenue challenges with strategic growth initiatives

Helius Medical Technologies faces challenges from program terminations impacting revenue and ongoing operating losses, but maintains a strong cash position with no debt.
Efforts to expand access to PoNS Therapy through strategic partnerships and sales initiatives present growth opportunities in the MS and stroke treatment markets.
The company's financial performance in Q2 2024 reflects a mixed picture of revenue decline, operational losses, and cash stability, with potential for growth pending reimbursement determinations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

NEWTOWN, Pa., June 20, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that its Portable Neuromodulation Stimulator (PoNS®) device has been awarded Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) accreditation by The Compliance Team (TCT), which is authorized by the Centers for Medicare & Medicaid Services (CMS) to accredit all DMEPOS products and services.

Helius Medical Technologies Announces DMEPOS Accreditation for PoNS

NEWTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Wednesday, June 21st at 11:30 A.M. ET

Helius Medical Technologies to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest

Newtown, Pennsylvania--(Newsfile Corp. - May 25, 2023) - Helius Medical Technologies, Inc. (NASDAQ: HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at LD Micro Invitational XIII 2023, at the Luxe Sunset Boulevard Hotel, California, as follows: Date: Wednesday, June 7, 2023Time: 4:00 PM PTWebcast: Click here Investors and attendees who would like to schedule a 1-on-1 meeting with Helius management are asked to contact LD Micro. About Helius Medical Technologies, Inc. Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain's ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases.

Helius Medical Technologies to Present at LD Micro Invitational XIII 2023

NEWTOWN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (Nasdaq:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for gait deficits, is excited to announce its participation in the prestigious Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting.  The event, which coincides with the May 30 observance of World MS Day, will take place from May 31 to June 3 at the Gaylord Rockies Resort & Convention Center in Aurora, Colo.  Helius will spotlight its cutting-edge Portable Neuromodulation Stimulator (PoNS®) device, which can improve gait deficit in people living with multiple sclerosis (MS).

Helius to Highlight Innovative PoNS Therapy™ at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting, in Commemoration of World MS Day

NEWTOWN, Pa., May 19, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT ) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, effective May 18, 2023, its independent directors approved an equity award under Helius' 2021 Inducement Plan, as a material inducement to an individual entering into employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.

Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Michelle Bilski – In-Site Communications Dane Andreeff – President and Chief Executive Officer Jeff Mathiesen – Chief Financial Officer Conference Call Participants Jonathan Aschoff – ROTH MKM Nick Sherwood – Maxim Group Operator Good day, and thank you for standing by. Welcome to the Helius Medical Technologies, Inc. Quarter One 2023 Earnings Conference Call.

Helius Medical Technologies, Inc. (HSDT) Q1 2023 Earnings Call Transcript

-- Company to host call at 4:30pm today -- NEWTOWN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter ended March 31, 2023.

Helius Medical Technologies, Inc. Reports First Quarter 2023 Financial Results

NEWTOWN, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its first quarter 2023 financial results on Thursday, May 11, 2023, after the market closes.

Helius Medical Technologies, Inc. to Release First Quarter 2023 Financial Results on May 11, 2023

MS, Stroke and mmTBI Cover Broader Set of Indications Across North American Markets MS, Stroke and mmTBI Cover Broader Set of Indications Across North American Markets

Helius Medical Technologies to Spotlight Expanded Authorizations for its PoNS Device at 2023 American Academy of Neurology Annual Meeting, Booth 1685

Allarity Therapeutics

Novavax

Sangamo Therapeutics

Clover Health Investments

Nektar Therapeutics

Vyne Therapeutics

Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing in pharma stocks can also mean heavy expenditures on research and testing for a drug that may not perform as well as scientists hope.

7 Sorry Pharma Stocks to Sell in April Before It's Too Late

NEWTOWN, Pa., March 23, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred Stock, par value $0.001 per share, for each outstanding share of Helius Class A common stock held of record on April 3, 2023. The outstanding shares of Series B Preferred Stock will vote together with the outstanding shares of the Company's Class A common stock as a single class exclusively with respect to any proposal to adopt an amendment to the Company's certificate of incorporation to reclassify the outstanding shares of the Company's Class A common stock into a smaller number of shares of such Class A common stock at a ratio specified in or determined in accordance with the terms of any such amendment, as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the foregoing matter, and will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law. Subject to certain limitations, each outstanding share of Series B Preferred Stock will have 1,000,000 votes per share (or 1,000 votes per one one-thousandth of a share of Series B Preferred Stock).

Helius Medical Technologies, Inc. Announces Distribution of Series B Preferred Stock to Holders of its Class A Common Stock Intended to Facilitate a Reverse Stock Split, if Necessary

-- Agreement extends existing partnership -- -- Collaboration makes HealthTech Connex the exclusive provider of PoNS Therapy in the Vancouver area and will greatly strengthen Helius's presence in the region -- NEWTOWN, Pa., March 22, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, and HealthTech Connex Inc. (“HTC”), a leading health technology company specializing in neurotechnology innovations, announced today that they have entered into an exclusive distribution agreement.

Helius Medical Technologies and HealthTech Connex Announce Exclusive Distribution Agreement for the Portable Neuromodulation Stimulator (PoNS®) Device

Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Michelle Bilski - In-Site Communications Dane Andreeff - President & Chief Executive Officer Jeffrey Mathiesen - Chief Financial Officer Antonella Favit-Van Pelt - Chief Medical Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Partners Destiny Hance - Ladenburg Thalmann Anthony Vendetti - Maxim Group Operator Good day, and thank you for standing by. Welcome to the Helius Medical Technologies Fourth Quarter and Year-End 2022 Earnings Conference Call.

Helius Medical Technologies, Inc. (HSDT) Q4 2022 Earnings Call Transcript

-- Full year 2022 revenue of $0.8 million, an increase of 51% over 2021 -- -- Year-end cash balance of $14.5 million --

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

-- PoNS already approved in Canada for treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury (TBI) and gait deficit due to mild and moderate symptoms from Multiple Sclerosis (MS) -- -- PoNS already approved in Canada for treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury (TBI) and gait deficit due to mild and moderate symptoms from Multiple Sclerosis (MS) --

Helius Medical Technologies Announces Authorization from Health Canada to Market Portable Neuromodulation Stimulator (PoNS®) Device for the Treatment of Gait Deficit Due to Mild and Moderate Symptoms from Stroke

NEWTOWN, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023, after the market closes.

Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

NEWTOWN, Pa., March 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at the 35th Annual ROTH Conference, March 12-14, 2023, Laguna Nigel, CA, as follows:

Helius Medical Technologies to Present at the 35th Annual ROTH Conference

Physical therapists in attendance can enhance their skillset with free on-site PoNS training Physical therapists in attendance can enhance their skillset with free on-site PoNS training

Helius Medical Technologies to Showcase PoNS Therapy™ at American Physical Therapy Association's 2023 Combined Sections Meeting

-- Q4 2022 revenue projected to range from $275,000 to $285,000 -- -- Full year 2022 revenue projected to range from $780,000 to $790,000 -- -- Unaudited year end cash balance of $14.5 million -- NEWTOWN, Pa., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2022, and provided a corporate update.

Helius Medical Technologies, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2022

NEWTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at the Virtual Q1 Investor Summit Microcap Event, as follows:

Helius Medical Technologies to Present at the Virtual Q1 Investor Summit Microcap Event, January 26, 2023

-- Fifth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects' adherence to PoNS ® therapy for gait improvement in Multiple Sclerosis -- NEWTOWN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the addition of Neurology Center of New England, P.C. (“NCNE”) to its Therapeutic Experience Program (TEP). NCNE joins four other Centers of Excellence in this company-sponsored open-label observational trial designed to evaluate the impact of subjects' adherence to Portable Neuromodulation Stimulator (PoNS) therapy in patients with multiple sclerosis (MS). The initiative will be led by Dr. Salvatore Napoli, Medical Director of NCNE.

Helius Medical Technologies, Inc. Announces Participation of Neurology Center of New England in its Therapeutic Experience Program

PTAP Lowers the Cost of PoNS Therapy™ for Qualified Americans PTAP Lowers the Cost of PoNS Therapy™ for Qualified Americans

Helius Extends its Patient Therapy Access Program (PTAP), Bringing the Benefits of its PoNS® Device to More People with Multiple Sclerosis

New Partnership with UpScript Provides Access to Care, Delivers PoNS Devices to Doorsteps New Partnership with UpScript Provides Access to Care, Delivers PoNS Devices to Doorsteps

Helius Launches UpScript Telehealth e-Commerce Site, Making it Easier for Americans with Multiple Sclerosis to Access Neurotech that can Improve their Ability to Walk

NEWTOWN, Pa., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT ) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, effective December 27, 2022, its independent directors approved an equity award under Helius' 2021 Inducement Plan, as a material inducement to an individual entering into employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.

Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

AMC Entertainment

CuriosityStream

Live Nation

Vir Biotechnology

Want to try an out-of-the-box approach? Tap AMC Entertainment (AMC), Live Nation Entertainment (LYV), CuriosityStream (CURI), Helius Medical Technologies (HSDT) and Vir Biotechnology (VIR).

News for Helius Medical Technologies Stock (HSDT)